Fennec Pharmaceuticals Inc. (FENC) Financial Analysis & Valuation | Quarter Chart
Fennec Pharmaceuticals Inc. (FENC)
FENCPrice: $6.12
Fair Value: 🔒
🔒score
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex T... more
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the cl... more
Description
Shares
| Market Cap | $175.05M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jeffrey S. Hackman |
| IPO Date | 2017-09-15 | CAGR | 1.06% |
| Employees | 32 | Website | www.fennecpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.01% | Total Yield | 0.01% |
FENC chart loading...
Fundamentals
Technicals
| Enterprise Value | $203.33M | P/E Ratio | -29.35 |
| Forward P/E | 6.42 | PEG Ratio | — |
| P/S Ratio | 3.9 | P/B Ratio | 5.45 |
| P/CF Ratio | -23.91 | P/FCF Ratio | -21.92 |
| EPS | $-0.26 | EPS Growth 1Y | 519.72% |
| EPS Growth 3Y | -62.62% | EPS Growth 5Y | -54.47% |
| Revenue Growth 1Y | -5.65% | Gross Margin | 0.92% |
| Operating Margin | -0.15% | Profit Margin | -0.23% |
| ROE | -2.36% | ROA | -0.15% |
| ROCE | -0.11% | Current Ratio | 6.34 |
| Quick Ratio | 6.19 | Cash Ratio | 3.5 |
| Debt/Equity | — | Interest Coverage | -3.16 |
| Altman Z Score | -0.34 | Piotroski Score | 3 |